Establishing the Carcinogenic Risk of Immunomodulatory Drugs

Toxicologic Pathology

Volumn 40, Issue 2, 2012, Pages 267-271

  Weaver, James L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

carcinogenicity; drugs; immunomodulatory

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; RAPAMYCIN; TACROLIMUS;

BURKITT LYMPHOMA; CANCER PATIENT; CANCER RISK; CARCINOGEN TESTING; CARCINOGENESIS; CARCINOGENICITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FOOD AND DRUG ADMINISTRATION; GAMMAHERPESVIRINAE; GENETIC ASSOCIATION; HEART LUNG TRANSPLANTATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOBLASTIC LYMPHOMA; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; LUNG TRANSPLANTATION; LYMPHOCRYPTOVIRUS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SINGLE DRUG DOSE; SKIN TUMOR; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; TUMOR VIRUS; UTERINE CERVIX CANCER; VIRUS HEPATITIS; VIRUS INFECTION; WART VIRUS;

ANIMALS; DRUG EVALUATION; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; RISK FACTORS;

HUMAN HERPESVIRUS 4; LYMPHOCRYPTOVIRUS; MACACA FASCICULARIS; MURINE HEPATITIS VIRUS; MUS;

EID: 84858774020     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311427711     Document Type: Article

References (33)

1. Askling J. van Vollenhoven R. F. Granath F. Raaschou P. Fored C. M. Baecklund E. Dackhammar C. Feltelius N. Cöster L. Geborek P. Jacobsson L. T. Lindblad S. Rantapää-Dahlqvist S. Saxne T. Klareskog L. (2009). Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60, 3180–89.
2. Brambilla G. Martelli A. (2009). Update on genotoxicity and carcinogenicity of 472 marketed pharmaceuticals. Mut Res 681, 209–29.
3. Cavaleiro-Pinto M. Peleteiro B. Lunet N. Barros H. (2011). Helicobacter pylori infection and gastric cardia cancer: Systematic review and meta-analysis. Cancer Causes Control 22, 375–87.
4. Centers for Disease Control and Prevention. (2008). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR Morb Mortal Wkly Rep 57(No. RR-10), 1–9.
5. Chang Y. Cesarman E. Pessin M. S. Lee F. Culpepper J. Knowles D. M. Moore P. S. (1994). Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266, 1865–69.
6. Cogliano V. Baan R. Straif K. Grosse Y. Secretan B. El Ghissassi F. (2005). Carcinogenicity of human papillomaviruses. Lancet Oncol 6, 204.
7. Davison A. J. (2002). Evolution of herpesviruses. Vet Microbiol 86, 69–88.
8. Diak P. Siegel J. La Grenade L. Choi L. Lemery S. McMahon A. (2010). Tumor necrosis factor α blockers and malignancy in children. Arthritis Rheum 62, 2517–24.
9. Diener R. (1983). Design of carcinogenicity studies: A backward glance. Toxicol Pathol 11, 37–40.
10. Ehlers B. Spiess K. Leendertz G. Peeters M. Boesch C. Gatherer D. McGeoch D. J. (2010). Lymphocryptovirus phylogeny and the origins of Epstein-Barr virus. J Gen Virol 91, 630–42.
11. Finley D. S. Pantuck A. J. Belldegrun A. S. (2011). Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 16s2, 4–13.
12. Fujimoto K. Honjo S. (1991) Presence of antibody to cyno-EBV in domestically bred cynomolgus monkey (Macaca fascicularis). J Med Primatol 20, 42–45.
13. Gutierrez-Dalmau A. Campistol J. M. (2007). Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs 67, 1167–98.
14. Grulich A. E. van Leeuwen M. T. Falster M. O. Vajdic C. M. (2007). Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370, 59–67.
15. Habis A Baskin GB Murphey-Corb M Levy LS. (1999). Simian AIDS-associated lymphoma in rhesus and cynomolgus monkeys recapitulates the primary pathobiological features of AIDS-associated non-Hodgkin's lymphoma. AIDS Res Hum Retrovir 15, 1389–1398.
16. Hwang S Wu TT Ton LM Kim KS Martinez-Guzman D Colantonio AD Uittenbogaart CH Sun R. (2008). Persistant gammaherpesvirus replication and dynamic interaction with the host In Vivo J Virol 82, 12498–12509.
17. ICH S1C(R2). (2008). Dose selection for carcinogenicity studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM074919.pdf. Accessed 1 Nov 2011.
18. Ishida T. Varavudhi P. (1992). Wild long-tailed macaques (Macaca fasicularis) in Thailand are highly infected with gamma herpes virus but not with simian T-lymphotropic retrovirus of type 1. Folia Primatol 59, 163–68.
19. Kauffman H. M. Cherikh W. S. McBride M. A. Cheng Y. Hanto D. W. (2006). Post-transplant de novo malignancies in renal transplant patients: the past and present. Transplant Int 19, 607–20.
20. Ko J. M. Velez N. F. Tsao H. (2010). Pathways to melanoma. Semin Cutan Med Surg 29, 210–17.
21. Ma S.-D. Hegde S. Young K. H. Sullivan R. Rajesh D. Zhou Y. Jankowska-Gan E. Burlingham W. J. Sun X. Gulley M. L. Tang W. Gumperz J. E. Kenney S. C. (2011). A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 85, 165–72.
22. McKhann C. F. (1969). Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 8, 209–12.
23. Melkus M. W. Estes J. D. Padgett-Thomas A. Gatlin J. Denton P. W. Othieno F. A. Wege A. K. Haase A. T. Garcia J. V. (2006). Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 12, 1316–22.
24. Mesri E. A. Cesarman E. Boshoff C. (2010). Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer 10, 707–19.
25. M.T., Nurmohamed, B.B.C., Dijkmans, Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis, Drugs, (2005), 65, 661-694
26. Palumbo A. Anderson K. (2011). Multiple myeloma. N Engl J Med 364, 1046–60.
27. Salavoura K. Kolialexi A. Tsangaris G. Mavrou A. (2008). Development of cancer in patients with primary immunodeficiencies. Anticancer Res 28, 1263–70.
28. Schmidtko J. Wang R. Wu C.-L. Mauiyyedi S. Harris N. L. Della Pelle P. Brousaides N. Zagachin L. Ferry J. A. Wang F. Kawai T. Sachs D. H. Cosimi A. B. Colvin R. B. (2002). Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplant 73, 1431–39.
29. Sunil-Chandra N. P. Arno J. Fazakerley J. Nash A. A. (1994). Lymphproliferative disease in mice infected with murine gammaherpesvirus 68. Am J Pathol 145, 818–26.
30. Tran H. Nourse J. Hall S. Green M. Griffiths L. Gandhi M. K. (2008). Immunodeficiency-associated lymphomas. Blood Rev 22, 261–81.
31. Vegso G. Toth M. Hidvegi M. Toronyi E. Langer R. M. Dinya E. Toth A. Perner F. Jaray J. (2007). Malignancies after renal transplantation during 33 years at a single center. Path Oncol Res 13, 63–69.
32. Wang C. C. Castillo J. J. (2011). Management of HIV-associated lymphomas. Med Health/Rhode Island 94, 4–6.
33. M., Yajima, K.I., Imadome, A., Nakagawa, S., Watanabe, K., Terashima, H., Nakamura, M., Ito, N., Shimizu, M., Honda, N., Yamamoto, S., Fujiwara, A new humanized mouse model of Epstein-Barr virus that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses, J Infect Dis, (2008), 198, 673-682